4893 items matching your search terms.

Improving delivery of secondary prophylaxis for rheumatic heart disease in remote Indigenous communities: study protocol for a stepped-wedge randomised trial

Ralph, A. P. Read, C. Johnston, V. de Dassel, J. L. Bycroft, K. Mitchell, A. Bailie, R. S. Maguire, G. P. Edwards, K. Currie, B. J. Kirby, A. Carapetis, J. R.
TRIALS, 2016     DOI:10.1186/s13063-016-1166-y

Myelin oligodendrocyte glycoprotein antibodies are associated with bilateral and recurrent optic neuritis and have a distinct radiological profile to multiple sclerosis or aquaporin-4 antibody-associated optic neuritis (P3.001)

Ramanathan, S. Prelog, K. Barnes, E. Tantsis, E. Reddel, S. Henderson, A. Vucic, O. Gorman, M. Benson, L. Alper, G. Riney, C. Barnett, M. Parratt, J. Hardy, T. Leventer, R. Merheb, V. Nosadini, M. Fung, V. Brilot, F. Dale, R.

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis

Ramanathan, S. Prelog, K. Barnes, E. H. Tantsis, E. M. Reddel, S. W. Henderson, A. P. Vucic, S. Gorman, M. P. Benson, L. A. Alper, G. Riney, C. J. Barnett, M. Parratt, J. D. Hardy, T. A. Leventer, R. J. Merheb, V. Nosadini, M. Fung, V. S. Brilot, F. Dale, R. C.
MULTIPLE SCLEROSIS, 2016     DOI:10.1177/1352458515593406

A novel mitochondrial inhibitor overcomes metabolic reprogramming and enhances the response of NRAS-mutant melanoma cells to MEK inhibition

Rao, A. Smith, L. Parmenter, T. Schreuders, J. Butt, T. Tiganis, T. Culllinane, C. Hogg, P. McArthur, G.

Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials

Regan, M. M. Francis, P. A. Pagani, O. Fleming, G. F. Walley, B. A. Viale, G. Colleoni, M. Lang, I. Gomez, H. L. Tondini, C. Pinotti, G. Price, K. N. Coates, A. S. Goldhirsch, A. Gelber, R. D.
JOURNAL OF CLINICAL ONCOLOGY, 2016     DOI:10.1200/JCO.2015.64.3171

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

Reith, C. Blackwell, L. Emberson, J. Mihaylova, B. Armitage, J. Fulcher, J. Keech, A. Simes, J. Baigent, C. Collins, R.
AMERICAN HEART JOURNAL, 2016     DOI:10.1016/j.ahj.2016.01.016

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial

Ribi, K. Luo, W. Bernhard, J. Francis, P. A. Burstein, H. J. Ciruelos, E. Bellet, M. Pavesi, L. Lluch, A. Visini, M. Parmar, V. Tondini, C. Kerbrat, P. Perello, A. Neven, P. Torres, R. Lombardi, D. Puglisi, F. Karlsson, P. Ruhstaller, T. Colleoni, M. Coates, A. S. Goldhirsch, A. Price, K. N. Gelber, R. D. Regan, M. M. Fleming, G. F.
JOURNAL OF CLINICAL ONCOLOGY, 2016     DOI:10.1200/JCO.2015.64.8675

Clinical outcomes associated with albuminuria in central Australia: a cohort study

Ritte, R. Luke, J. Nelson, C. Brown, A. O'Dea, K. Jenkins, A. Best, J. D. McDermott, R. Daniel, M. Rowley, K.
BMC NEPHROLOGY, 2016     DOI:10.1186/s12882-016-0328-1

Quality of life to predict overall survival in women with platinum-resistant ovarian cancer

Roncolato, F Gibbs, E. Lee, C. Davies, L.C. Gebski, V. Friedlander, M. Hilpert, F. Wenzel, L.B. Stockler, M.R. King, M.T. Pujade-Lauraine, E

Baseline quality of life as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer: the GCIG Symptom Benefit study

Roncolato, F. O'Connell, R.O. Buizen, L. Joly, F. Lanceley, A. Hilpert, F. Okamoto, A. Aotani, E. Pignata, S Donnellan, P.P. Oza, A.M. Avall-Lundqvist, E. Berek, J.S. Sjoquist, K.M. Gillies, K. Stockler, M.R. King, M.T. Friedlander, M. GCIG Symptom Benefit Study Group,

The effect of pulmonary function testing on bleomycin dosing in germ cell tumours

Roncolato, F. T. Chatfield, M. Houghton, B. Toner, G. Stockler, M. Thomson, D. Friedlander, M. Gurney, H. Rosenthal, M. Grimison, P. Australian, New Zealand Urogenital Prostate Cancer Trials, Group
INTERNAL MEDICINE JOURNAL, 2016     DOI:10.1111/imj.13158

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Sabatine, M. S. Giugliano, R. P. Keech, A. Honarpour, N. Wang, H. Liu, T. Wasserman, S. M. Scott, R. Sever, P. S. Pedersen, T. R.
AMERICAN HEART JOURNAL, 2016     DOI:10.1016/j.ahj.2015.11.015

Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia)

Sajjad, M. A. Holloway, K. L. Kotowicz, M. A. Livingston, P. M. Khasraw, M. Hakkennes, S. Dunning, T. L. Brumby, S. Page, R. S. Pedler, D. Sutherland, A. Venkatesh, S. Brennan-Olsen, S. L. Williams, L. J. Pasco, J. A.
J PUBLIC HEALTH RES, 2016     DOI:10.4081/jphr.2016.678

Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer

Schofield, P. E. Stockler, M. R. Zannino, D. Tebbutt, N. C. Price, T. J. Simes, R. J. Wong, N. Pavlakis, N. Ransom, D. Moylan, E. Underhill, C. Wyld, D. Burns, I. Ward, R. Wilcken, N. Jefford, M.
SUPPORTIVE CARE IN CANCER, 2016     DOI:10.1007/s00520-015-2792-8

Glycaemic variability in type 1 diabetes patients is better with continuous subcutaneous insulin infusion therapy than with multiple daily injection treatment

Scott, E. Calandro, D. Januszewski, A. O'Neal, D Fulcher, G. Jenkins, A.